{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T08:09:28Z","timestamp":1789978168023,"version":"4.0.1"},"reference-count":154,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2016,6,12]],"date-time":"2016-06-12T00:00:00Z","timestamp":1465689600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["CA 107476, CA 168762, and CA186781"],"award-info":[{"award-number":["CA 107476, CA 168762, and CA186781"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["American J Hematol"],"published-print":{"date-parts":[[2016,7]]},"abstract":"<jats:p>Multiple myeloma accounts for approximately 10% of hematologic malignancies.The diagnosis requires \u226510% clonal bone marrow plasma cells or a biopsy proven plasmacytoma plus evidence of one or more multiple myeloma defining events (MDE): CRAB (hyper<jats:styled-content>c<\/jats:styled-content>alcemia, <jats:styled-content>r<\/jats:styled-content>enal failure, <jats:styled-content>a<\/jats:styled-content>nemia, or lytic <jats:styled-content>b<\/jats:styled-content>one lesions) features felt related to the plasma cell disorder, bone marrow clonal plasmacytosis \u226560%, serum involved\/uninvolved free light chain (FLC) ratio \u2265100 (provided involved FLC is \u2265100 mg\/L), or &gt;1 focal lesion on magnetic resonance imaging. Patients with del(17p), t(14;16), and t(14;20) have high\u2010risk multiple myeloma. Patients with t(4;14) translocation and gain(1q) have intermediate\u2010risk. All others are considered standard\u2010risk. Initial treatment consists of bortezomib, lenalidomide, dexamethasone (VRD). In high\u2010risk patients, carfilzomib, lenalidomide, dexamethasone (KRD) is an alternative to VRD. In eligible patients, initial therapy is given for approximately 3\u20134 months followed by autologous stem cell transplantation (ASCT). Standard risk patients can opt for delayed ASCT at first relapse. Patients not candidates for transplant are treated with Rd until progression, or alternatively, a triplet regimen such as VRD for approximately 12\u201318 months. After ASCT, lenalidomide maintenance is considered for standard risk patients especially in those who are not in very good partial response or better, while maintenance with a bortezomib\u2010based regimen is needed for patients with intermediate or high\u2010risk disease. Patients with indolent relapse can be treated with 2\u2010drug or 3\u2010drug combinations. Patients with more aggressive relapse require a triplet regimen or a combination of multiple active agents. Am. J. Hematol. 91:720\u2013734, 2016. \u00a9 2016 Wiley Periodicals, Inc.<\/jats:p>","DOI":"10.1002\/ajh.24402","type":"journal-article","created":{"date-parts":[[2016,6,13]],"date-time":"2016-06-13T04:39:59Z","timestamp":1465792799000},"page":"719-734","source":"Crossref","is-referenced-by-count":381,"title":["Multiple myeloma: 2016 update on diagnosis, risk\u2010stratification, and management"],"prefix":"10.1002","volume":"91","author":[{"given":"S. Vincent","family":"Rajkumar","sequence":"first","affiliation":[{"name":"Division of Hematology Mayo Clinic Rochester Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,6,12]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70442-5"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23810"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21332"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20652"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2009.134"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.4065\/78.1.21"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.336"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12346"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2011.29"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-12-194241"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-12-195008"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa01133202"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa054494"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)60482-5"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.34"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2012.06.014"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa070389"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.86"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.48.4923"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.4065\/81.12.1575"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.4065\/mcp.2009.0603"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2009.160"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.20794"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2006.04.014"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2009.89"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.307"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404284"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-10-299487"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-11-390658"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2015.92"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc746"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1204641"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V100.4.1417.h81602001417_1417_1424"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(03)01195-1"},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70143-7"},{"key":"e_1_2_11_37_1","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2015.91"},{"key":"e_1_2_11_38_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U"},{"key":"e_1_2_11_39_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.242"},{"key":"e_1_2_11_40_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2009.61"},{"key":"e_1_2_11_41_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.61.2267"},{"key":"e_1_2_11_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2013.01.019"},{"key":"e_1_2_11_43_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2011.63"},{"key":"e_1_2_11_44_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.236"},{"key":"e_1_2_11_45_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1300439"},{"key":"e_1_2_11_46_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.313"},{"key":"e_1_2_11_47_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199911183412102"},{"key":"e_1_2_11_48_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa043445"},{"key":"e_1_2_11_49_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-07-2817"},{"key":"e_1_2_11_50_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-04-015909"},{"key":"e_1_2_11_51_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra041875"},{"key":"e_1_2_11_52_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.0221"},{"key":"e_1_2_11_53_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.14.1853"},{"key":"e_1_2_11_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(09)70284-0"},{"key":"e_1_2_11_55_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-11-538835"},{"key":"e_1_2_11_56_1","first-page":"1498","article-title":"Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: Results of an IFM phase II study","volume":"91","author":"Harousseau J","year":"2006","journal-title":"Haematologica"},{"key":"e_1_2_11_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61537-2"},{"key":"e_1_2_11_58_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.21.0948"},{"key":"e_1_2_11_59_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0801479"},{"key":"e_1_2_11_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(10)70187-X"},{"key":"e_1_2_11_61_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.29.8216"},{"key":"e_1_2_11_62_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61424-9"},{"key":"e_1_2_11_63_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2009.26"},{"key":"e_1_2_11_64_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-11-395749"},{"key":"e_1_2_11_65_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-02-268862"},{"key":"e_1_2_11_66_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-05-425934"},{"key":"e_1_2_11_67_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-03-563759"},{"key":"e_1_2_11_68_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2014.02.005"},{"key":"e_1_2_11_69_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)01120-4"},{"key":"e_1_2_11_70_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1505654"},{"key":"e_1_2_11_71_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70440-1"},{"key":"e_1_2_11_72_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1177319"},{"key":"e_1_2_11_73_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1244851"},{"key":"e_1_2_11_74_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1244917"},{"key":"e_1_2_11_75_1","doi-asserted-by":"publisher","DOI":"10.1038\/8466"},{"key":"e_1_2_11_76_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.11.030"},{"key":"e_1_2_11_77_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-07-167767"},{"key":"e_1_2_11_78_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2009.123"},{"key":"e_1_2_11_79_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1506348"},{"key":"e_1_2_11_80_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70443-7"},{"key":"e_1_2_11_81_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.0638"},{"key":"e_1_2_11_82_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402551"},{"key":"e_1_2_11_83_1","doi-asserted-by":"crossref","unstructured":"Durie BGM HoeringA RajkumarSV et al. Bortezomib lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (asct): Results of the randomized phase iii trial swOG S0777. ASH Annual Meeting Abstracts2015.","DOI":"10.1182\/blood.V126.23.25.25"},{"key":"e_1_2_11_84_1","unstructured":"MoreauP HulinC MacroM et al. Bortezomib thalidomide and dexamethasone (vtd) is superior to bortezomib cyclophosphamide and dexamethasone (vcd) prior to autologous stem cell transplantation for patients with de novo multiple myeloma. Results of the Prospective IFM 2013\u201004 Trial. ASH Annual Meeting Abstracts2015."},{"key":"e_1_2_11_85_1","first-page":"A391","article-title":"Autologous transplantation for multiple myeloma in the era of new drugs: A phase iii study of the intergroupe francophone du myelome (ifm\/dfci 2009 trial)","volume":"126","author":"Michel A","year":"2015","journal-title":"ASH Annu Meet Abst"},{"key":"e_1_2_11_86_1","doi-asserted-by":"publisher","DOI":"10.4065\/83.10.1142"},{"key":"e_1_2_11_87_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-06-297853"},{"key":"e_1_2_11_88_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-11-568907"},{"key":"e_1_2_11_89_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-01-550020"},{"key":"e_1_2_11_90_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2014.115162"},{"key":"e_1_2_11_91_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404801"},{"key":"e_1_2_11_92_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-04-205013"},{"key":"e_1_2_11_93_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2009.127"},{"key":"e_1_2_11_94_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.31.6844"},{"key":"e_1_2_11_95_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-03-344333"},{"key":"e_1_2_11_96_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2405062"},{"key":"e_1_2_11_97_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-05-355081"},{"key":"e_1_2_11_98_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2007.06639.x"},{"key":"e_1_2_11_99_1","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1182\/blood-2010-01-264333","article-title":"Total therapy 3 for multiple myeloma: Prognostic implications of cumulative dosing and premature discontinuation of VTD maintenance components, bortezomib, thalidomide and dexamethasone, relevant to all phases of therapy","volume":"116","author":"Rhee F","journal-title":"Blood"},{"key":"e_1_2_11_100_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-11-255620"},{"key":"e_1_2_11_101_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70081-X"},{"key":"e_1_2_11_102_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2010.82"},{"key":"e_1_2_11_103_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-04-422683"},{"key":"e_1_2_11_104_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V122.21.538.538"},{"key":"e_1_2_11_105_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(06)68338-4"},{"key":"e_1_2_11_106_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-08-237974"},{"key":"e_1_2_11_107_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.1610"},{"key":"e_1_2_11_108_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2010.01524.x"},{"key":"e_1_2_11_109_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2010.313"},{"key":"e_1_2_11_110_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-03-341669"},{"key":"e_1_2_11_111_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V122.21.536.536"},{"key":"e_1_2_11_112_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-10-078022"},{"key":"e_1_2_11_113_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.12.3832"},{"key":"e_1_2_11_114_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-07-169565"},{"key":"e_1_2_11_115_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1112704"},{"key":"e_1_2_11_116_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-12-613927"},{"key":"e_1_2_11_117_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199607113350204"},{"key":"e_1_2_11_118_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa022340"},{"key":"e_1_2_11_119_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-01-0073"},{"key":"e_1_2_11_120_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(03)01077-5"},{"key":"e_1_2_11_121_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V92.9.3131"},{"key":"e_1_2_11_122_1","first-page":"685a","article-title":"Front\u2010line or rescue autologous bone marrow transplantation (ABMT) following a first course of high dose melphalan (HDM) in multiple myeloma (MM). Preliminary results of a prospective randomized trial (CIAM) protocol","volume":"88","author":"Facon T","year":"1996","journal-title":"Blood"},{"key":"e_1_2_11_123_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.5807"},{"key":"e_1_2_11_124_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa032290"},{"key":"e_1_2_11_125_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.10.2509"},{"key":"e_1_2_11_126_1","first-page":"S59","article-title":"Single versus tandem high dose therapy (HDT) supported with autologous blood stem cell (ABSC) transplantation using unselected or CD34\u2010enriched ABSC: Results of a two by two designed randomized trial in 230 young patients with multiple myeloma (MM)","volume":"4","author":"Fermand JP","year":"2003","journal-title":"Hematol J"},{"key":"e_1_2_11_127_1","first-page":"S61","article-title":"Single v. tandem autolgous transplantation in multiple myeloma: The GMMG experience","volume":"4","author":"Goldschmidt H.","year":"2003","journal-title":"Hematol J"},{"key":"e_1_2_11_128_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.39.6820"},{"key":"e_1_2_11_129_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70243-1"},{"key":"e_1_2_11_130_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa065464"},{"key":"e_1_2_11_131_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-12-173526"},{"key":"e_1_2_11_132_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-05-022962"},{"key":"e_1_2_11_133_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.18.8573"},{"key":"e_1_2_11_134_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1114138"},{"key":"e_1_2_11_135_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1114083"},{"key":"e_1_2_11_136_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2012.100"},{"key":"e_1_2_11_137_1","doi-asserted-by":"publisher","DOI":"10.4065\/79.7.867"},{"key":"e_1_2_11_138_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2011.196"},{"key":"e_1_2_11_139_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70380-2"},{"key":"e_1_2_11_140_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1411321"},{"key":"e_1_2_11_141_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00464-7"},{"key":"e_1_2_11_142_1","doi-asserted-by":"crossref","unstructured":"PhilippeMoreau Tam\u00e1sMasszi NorbertGrzasko et al. Ixazomib an Investigational Oral Proteasome Inhibitor (PI) in Combination with Lenalidomide and Dexamethasone (IRd) Significantly Extends Progression\u2010Free Survival (PFS) for Patients (Pts) with Relapsed and\/or Refractory Multiple Myeloma (RRMM): The Phase 3 Tourmaline\u2010MM1 Study (NCT01564537). ASH Annual Meeting Abstracts2015.","DOI":"10.1182\/blood.V126.23.727.727"},{"key":"e_1_2_11_143_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa070594"},{"key":"e_1_2_11_144_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa070596"},{"key":"e_1_2_11_145_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.99"},{"key":"e_1_2_11_146_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.22.2679"},{"key":"e_1_2_11_147_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.10.5460"},{"key":"e_1_2_11_148_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.23.6802"},{"key":"e_1_2_11_149_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2010.190"},{"key":"e_1_2_11_150_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-04-348896"},{"key":"e_1_2_11_151_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0503221102"},{"key":"e_1_2_11_152_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.46.7068"},{"key":"e_1_2_11_153_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-09-568899"},{"key":"e_1_2_11_154_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.1993.tb00148.x"},{"key":"e_1_2_11_155_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1996.212"}],"container-title":["American Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fajh.24402","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.24402","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T20:57:59Z","timestamp":1695502679000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.24402"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6,12]]},"references-count":154,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2016,7]]}},"alternative-id":["10.1002\/ajh.24402"],"URL":"https:\/\/doi.org\/10.1002\/ajh.24402","archive":["Portico"],"relation":{},"ISSN":["0361-8609","1096-8652"],"issn-type":[{"value":"0361-8609","type":"print"},{"value":"1096-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,6,12]]}}}